An Open Label, Registry Study of the Safety of Iluvien 190 Micrograms Intravitreal Implant in Applicator

Trial Profile

An Open Label, Registry Study of the Safety of Iluvien 190 Micrograms Intravitreal Implant in Applicator

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms IRISS
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 23 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2020.
    • 23 Oct 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2020.
    • 23 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top